Effects of EGFR Mutations on NSCLC Patients Treated by Ramucirumab plus Docetaxel

Abstract

The present paper attempted to define the effects of epidermal growth factor receptor (EGFR) mutations on patients with non-small cell lung cancer (NSCLC) treated by ramucirumab plus docetaxel. Of the 82 enrolled patients, 48 underwent EGFR mutations, showing relevance to sex and smoking history (P<0.05). The analysis yielded that EGFR-mutant (EGFR-Mut) group had a higher objective response rate versus EGFR-wild-type (EGFR-Wt) group (P<0.05). Subsequent to treatment, serum VEGF, bFGF, HDGF, CEA, CA153, CYFRA21-1 and CA199 levels dropped more significantly in EGFR-Mut group (P<0.05). Beyond that, EGFR-Mut exhibited a lower ZPS score and a higher KPS score versus EGFR-Wt group (P<0.05). Further, EGFR-Mut patients displayed strikingly longer median survival time versus EGFR-Wt patients (P<0.05). Ramucirumab plus docetaxel can safely inhibit tumour angiogenesis and regulate the levels of serum tumour markers. EGFR-Mut NSCLC patients with brain metastasis have better treatment outcomes and longer survival.